The clinical spectrum of Castleman's disease.
Am. J. Hematol., Nov;87(11):997-1002 (2012)
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
Gynecol. Oncol., Feb;124(2):210-5 (2012)
Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial.
Am. J. Clin. Oncol., Oct;35(5):418-23 (2012)
Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial.
J Gastrointest Cancer., 38(1):10-4 (2007)
Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey.
Leuk. Res., May;32(5):691-8 (2008)
Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.
J. Clin. Oncol., Jun;25(18):2567-72 (2007)
Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia.
Am. J. Hematol., May;82(5):400-2 (2007)
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Blood., Sep;108(5):1497-503 (2006)
Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
J. Clin. Oncol., Mar;24(7):1052-6 (2006)
A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
Invest New Drugs., Jul;24(4):327-33 (2006)
The Office of Advanced Technology: providing focus on the piloting and implementation of new technology.
J Healthc Inf Manag., 18(4):27-32 (2004)
Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
Am. J. Clin. Oncol., Oct;20(5):500-4 (1997)
A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Cancer J Sci Am., 3(5):297-302 (1997 Sep-Oct)
Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.
J. Clin. Oncol., Aug;8(8):1327-34 (1990)